Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

Alpha Tau Medical LTD.2 enrolled

Overview

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

This will be a prospective, open label, single arm, controlled study, assessing the safety and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive seeds inserted into the tumor. This approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients. Superficial lesions with histopathological confirmation of malignancy will be treated using DaRT seeds. Reduction in tumor volume and evaluation the percent of necrotic tissue in the tumor 30-45 days after DaRT seeds insertion (15-30 days after seed removal) will be assessed. Safety will be assessed by the cumulative incidence, worst severity and frequency of adverse events (AEs) observed including the follow-up period.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Skin Cancer Mucosal Neoplasm of Oral Cavity Soft Tissue Neoplasm

Interventions

Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)DEVICE

An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with histopathological confirmation of cutaneous and/or mucosal and/or superficial soft tissue malignant neoplasia. * Subjects with a tumor size ≤ 5 centimeters in the longest diameter. * Subjects' age is over 18 years old. * Subjects' ECOG Performance Status Scale is \< 2. * Subjects' life expectancy is more than 6 months. * Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test. * Subjects are able and willing to sign an informed consent form. Exclusion Criteria: * Subject has a tumor with a maximal diameter \> 5 centimeters. * Subjects' ECOG Performance Status Scale is \> 3. * Subject has a tumor of Keratoacanthoma histology. * Patients with moribund diseases, e.g., autoimmune diseases, vasculitis, etc. * Patients under systemic immunosuppressive and/or corticosteroid treatment. Patients taking corticosteroid inhalers are eligible.

Locations (1)

IRCCS Istituto Dermatologico S. Gallicano, IFO - Istituti Fisioterapici Ospitalieri - Dermatologia Oncologica e Prevenzione

Rome, Lazio, Italy

Outcomes

Primary Outcomes

Evaluate the safety of the DaRT treatment

The study primary objective is to evaluate the safety of the DaRT treatment in terms of incidence of device related Serious Adverse Events (SAE).

Time frame: 5-7 weeks after DaRT seed insertion.

Secondary Outcomes

Evaluation the effectiveness of the treatment.

Evaluation on the effectiveness of the DaRT treatment, in terms of tumor volume reduction.

Time frame: Tumor volume will be measured during screening, 5 and 30-45 days post DaRT after treatment using CT.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.